Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1558-1566

  Landowski, Terry H ^a   Gard, Jaime ^a   Pond, Erika ^a   Pond, Gerald D ^a   Nagle, Raymond B ^a   Geffre, Christopher P ^a   Cress, Anne E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J8H; UNCLASSIFIED DRUG; ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CONTROLLED STUDY; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN TARGETING; TUMOR GROWTH; XENOGRAFT; ANIMAL; BONE NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOBLAST; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHA6; MALE; MICE; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902650414     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0962     Document Type: Article

References (50)

1. Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ. The role of the bone microenvironment in skeletal metastasis. J Bone Oncol 2013;2:47-57.
2. Thobe M, Clark RJ, Bainer RO, Prasad SM, Rinker-Schaeffer CW. From prostate to bone: key players in prostate cancer bone metastasis. Cancers 2011;3:478-93.
3. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
4. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011;21:47-55.
5. Morris MJ, Scher HI. Clinical approaches to osseous metastases in prostate cancer. Oncologist 2003;8:161-73. (Pubitemid 36428282)
6. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011;8:357-68.
7. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The α6 β1 and α6 β4 integrins in human prostate cancer progression. Cancer Metastasis Rev 1995; 14:219-28.
8. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA. High expression level of α6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995;55:901-6.
9. Yamamoto H, Masters JR, Dasgupta P, Chandra A, Popert R, Freeman A, et al. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. PLoS ONE e46979 doi. 2012;7:11.
10. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, MacSwords J, et al. Integrin α6 regulates glioblastoma stem cells. Cell Stem Cell 2010;6:421-32.
11. Gu YC, Kortesmaa J, Tryggvason K, Persson J, Ekblom P, Jacobsen SE, et al. Laminin isoform-specific promotion of adhesion and migration of human bone marrow progenitor cells. Blood 2003;101:877-85. (Pubitemid 36139354)
12. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multi-lineage engraftment. Science 2011;333:218-21.
13. Qian H, Georges-Labouesse E, Nystrom A, Domogatskaya A, Tryggvason K, Jacobsen SE, et al. Distinct roles of integrins α6 and α4 in homing of fetal liver hematopoietic stem and progenitor cells. Blood 2007;110:2399-407. (Pubitemid 47523160)
14. Domogatskaya A, Rodin S, Boutaud A, Tryggvason K. Laminin-511 but not -332, -111, or -411 enables mouse embryonic stem cell self-renewal in vitro. Stem Cells 2008;26:2800-9.
15. Siler U, Seiffert M, Puch S, Richards A, Torok-Storb B, Müller CA, et al. Characterization and functional analysis of laminin isoforms in human bone marrow. Blood 2000;96:4194-203.
16. Demetriou MC, Cress AE. Integrin clipping: a novel adhesion switch? J Cell Biochem 2004;91:26-35.
17. Demetriou MC, Pennington ME, Nagle RB, Cress AE. Extracellular α6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res 2004;294:550-8. (Pubitemid 38326751)
18. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 2001;20:287-96. (Pubitemid 34595272)
19. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55. (Pubitemid 350002982)
20. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. Integrin α6 cleavage: a novel modification to modulate cell migration. Exp Cell Res 2007;313:1080-9. (Pubitemid 46427820)
21. Ports MO, Nagle RB, Pond GD, Cress AE. Extracellular engagement of α6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 2009;69:5007-14.
22. Sroka IC, Pond GD, Nagle RB, Porreca F, King T, Pestano G, et al. Human cell surface receptors as molecular imaging candidates for metastatic prostate cancer. Open Prost Cancer J 2009;2:59-66.
23. Hogervorst F, Kuikman I, Noteboom E, Sonnenberg A. The role of phosphorylation in activation of the α6A β1 laminin receptor. J Biol Chem 1993;268:18427-30. (Pubitemid 23273767)
24. Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, et al. Integrin switching regulates normal trophoblast invasion. Development 1994;120:3657-66. (Pubitemid 24367008)
25. Sonnenberg A, Janssen H, Hogervorst F, Calafat J, Hilgers J. A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. J Biol Chem 1987;262:10376-83.
26. Sroka IC, Chen ML, Cress AE. Simplified purification procedure of laminin-332 and laminin-511 from human cell lines. Biochem Biophys Res Commun 2008;375:410-3.
27. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, et al. The role of α6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS ONE 2008;3:e3535.
28. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol 2005;17:509-16. (Pubitemid 41267165)
29. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87. (Pubitemid 35283958)
30. Tsuchida J, Ueki S, Saito Y, Takagi J. Classification of 'activation' antibodies against integrin β1 chain. FEBS Lett 1997;416:212-6. (Pubitemid 27462791)
31. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007;67:3970-5. (Pubitemid 46762187)
32. Si W, Kang Q, Luu HH, Park JK, Luo Q, Song W-X, et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 2006;26:2955-64.
33. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006;119:4803-10. (Pubitemid 46017793)
34. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013;63:309-20.
35. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
36. Weis SM, Cheresh DA. αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011;1:a006478.
37. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2011;2:1159-65.
38. David E, Blanchard F, Heymann MF, De PG, Gouin F, Redini F, et al. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011;2011:932451.
39. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003;22:7396-402. (Pubitemid 37487165)
40. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Target 2012;13:1308-23.
41. Rashid KA, Stern JN, Ahmed AR. Identification of an epitope within human integrin α6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid. J Immunol 2006;176:1968-77. (Pubitemid 43134343)
42. Mignogna M, Lanza A, Rossiello L, Ruocco V, Ahmed AR. Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid. Clin Exp Immunol 2006;145:28-35. (Pubitemid 43893929)
43. Roodman GD. Mechanisms of bone metastasis. Discov Med 2004;4:144- 8.
44. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48:6-15.
45. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011;29:3695-704.
46. Yamashita Y, Aoki T, Hanagiri T, Yoshii C, Mukae H, Uramoto H, et al. Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Skeletal Radiol 2012;41:409-14.
47. Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med 2012;228:163-8.
48. Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, Vestita GD, et al. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 2008;80:59-64. (Pubitemid 351951362)
49. Jun JI, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 2010;12:676-85.
50. Chiechi A, Novello C, Magagnoli G, Petricoin EF, Deng J, Benassi MS, et al. Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res 2013;19:2473-85.